BID 610

BID 610, also known as KSI-301, is an investigational drug developed as a potential treatment for retinal diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema (DME). It is designed to be administered via intravitreal injection and works by using a new formulation that allows for extended release of the active compound, potentially providing longer-lasting therapeutic effects compared to traditional treatments.